U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07456839) titled 'A Mutiple-dose Study of IBI3033 in Healthy Participants' on Feb. 27.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 8-week treatment period and 8-week follow-up period.
Study Start Date: March 24
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Placebo
Participants in placebo group will receive placebo SC.
DRUG: IBI3033
Participants in IBI3033 gr...